IL6 and adrenal gland pheochromocytoma: A study analyzing biomarker profiles in PCC patients who reported symptom improvement after extracorporeal therapeutic apheresis observed a decrease in autoantibodies, lipids, and inflammation markers, including IL-1beta, IL-6, and CRP (Achleitner et al., 2023).